Research programme: T-cell adoptive immunotherapy - Cellectis

Drug Profile

Research programme: T-cell adoptive immunotherapy - Cellectis

Alternative Names: UCART 123; UCART 22; UCART 38; UCART CS1

Latest Information Update: 22 Feb 2017

Price : $50

At a glance

  • Originator Cellectis
  • Developer Cellectis; Pfizer; Servier; University College London
  • Class CAR-T cell therapies
  • Mechanism of Action Cell replacements; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Multiple myeloma; Solid tumours

Most Recent Events

  • 06 Feb 2017 The US FDA approves IND application for UCART 123 in Acute myeloid leukaemia (Blastic plasmacytoid dendritic cell neoplasm)
  • 03 Jan 2017 Cellectis files an IND application with the US FDA for Acute myeloid leukemia and Blastic plasmacytoid dendritic cell neoplasm
  • 15 Dec 2016 Recombinant DNA Advisory Committee approves two phase I study protocols of UCART 123 in Acute myeloid leukaemia and Blastic plasmacytoid dendritic cell neoplasm
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top